RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Revenue increased 11.4 per cent to Rs. 8,545 crore
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Subscribe To Our Newsletter & Stay Updated